@article{FrankeFaraoneAshersonetal.2012,
  author    = {Franke, B. and Faraone, S. V. and Asherson, P. and Buitelaar, J. and Bau, C. H. D. and Ramos-Quiroga, J. A. and Mick, E. and Grevet, E. H. and Johansson, S. and Haavik, J. and Lesch, K.-P. and Cormand, B. and Reif, A.},
  title     = {The genetics of attention deficit/hyperactivity disorder in adults, a review},
  series = {Molecular Psychiatry},
  volume    = {17},
  journal   = {Molecular Psychiatry},
  doi       = {10.1038/mp.2011.138},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-124677},
  pages     = {960-987},
  year      = {2012},
  abstract  = {The adult form of attention deficit/hyperactivity disorder (aADHD) has a prevalence of up to 5\% and is the most severe long-term outcome of this common neurodevelopmental disorder. Family studies in clinical samples suggest an increased familial liability for aADHD compared with childhood ADHD (cADHD), whereas twin studies based on self-rated symptoms in adult population samples show moderate heritability estimates of 30-40\%. However, using multiple sources of information, the heritability of clinically diagnosed aADHD and cADHD is very similar. Results of candidate gene as well as genome-wide molecular genetic studies in aADHD samples implicate some of the same genes involved in ADHD in children, although in some cases different alleles and different genes may be responsible for adult versus childhood ADHD. Linkage studies have been successful in identifying loci for aADHD and led to the identification of LPHN3 and CDH13 as novel genes associated with ADHD across the lifespan. In addition, studies of rare genetic variants have identified probable causative mutations for aADHD. Use of endophenotypes based on neuropsychology and neuroimaging, as well as next-generation genome analysis and improved statistical and bioinformatic analysis methods hold the promise of identifying additional genetic variants involved in disease etiology. Large, international collaborations have paved the way for well-powered studies. Progress in identifying aADHD risk genes may provide us with tools for the prediction of disease progression in the clinic and better treatment, and ultimately may help to prevent persistence of ADHD into adulthood.},
  language  = {en}
}
@article{ZieglerRichterMahretal.2016,
  author    = {Ziegler, C. and Richter, J. and Mahr, M. and Gajewska, A. and Schiele, M.A. and Gehrmann, A. and Schmidt, B. and Lesch, K.-P. and Lang, T. and Helbig-Lang, S. and Pauli, P. and Kircher, T. and Reif, A. and Rief, W. and Vossbeck-Elsebusch, A.N. and Arolt, V. and Wittchen, H.-U. and Hamm, A.O. and Deckert, J. and Domschke, K.},
  title     = {MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy},
  series = {Translational Psychiatry},
  journal   = {Translational Psychiatry},
  number    = {6},
  doi       = {10.1038/tp.2016.41},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-164422},
  pages     = {e773},
  year      = {2016},
  abstract  = {Epigenetic signatures such as methylation of the monoamine oxidase A (MAOA) gene have been found to be altered in panic disorder (PD). Hypothesizing temporal plasticity of epigenetic processes as a mechanism of successful fear extinction, the present psychotherapy-epigenetic study for we believe the first time investigated MAOA methylation changes during the course of exposure-based cognitive behavioral therapy (CBT) in PD. MAOA methylation was compared between N=28 female Caucasian PD patients (discovery sample) and N=28 age- and sex-matched healthy controls via direct sequencing of sodium bisulfite-treated DNA extracted from blood cells. MAOA methylation was furthermore analyzed at baseline (T0) and after a 6-week CBT (T1) in the discovery sample parallelized by a waiting time in healthy controls, as well as in an independent sample of female PD patients (N=20). Patients exhibited lower MAOA methylation than healthy controls (P<0.001), and baseline PD severity correlated negatively with MAOA methylation (P=0.01). In the discovery sample, MAOA methylation increased up to the level of healthy controls along with CBT response (number of panic attacks; T0-T1: +3.37±2.17\%), while non-responders further decreased in methylation (-2.00±1.28\%; P=0.001). In the replication sample, increases in MAOA methylation correlated with agoraphobic symptom reduction after CBT (P=0.02-0.03). The present results support previous evidence for MAOA hypomethylation as a PD risk marker and suggest reversibility of MAOA hypomethylation as a potential epigenetic correlate of response to CBT. The emerging notion of epigenetic signatures as a mechanism of action of psychotherapeutic interventions may promote epigenetic patterns as biomarkers of lasting extinction effects.},
  language  = {en}
}